🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Establishment of NAFLD Cohort and Development of Fibrosis Markers

Recruitingn/aAges 18 Years - anyAllSeoul National University Boramae Hospital
NCT02206841 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This study is designed for establishment of non-alcoholic fatty liver disease patients cohort to development of markers to predict histologic progression of liver fibrosis.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients with histologically confirmed fatty liver disease * Patients with radiologically confirmed fatty liver disease Exclusion Criteria: * History of significant alcohol consumption * Viral hepatitis * Autoimmune hepatitis * Metabolic diseases (e.g. hemochromatosis, M. Wilson, alpha 1-antitrypsin deficiency) * Hepatotoxic medication (e.g. amiodarone)
💊

What it tests

  • Liver biopsy
  • ARFI
  • SWE
  • Transient elastography
📍

Where

1 site
Seoul Metropolitan Government Seoul National University
Seoul, South Korea
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy